文献速递乳腺骨肌PETCT

18F-FDG PET/CT评估激素受体阳性骨主导型转移性乳腺癌的治疗反应

18F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer.
PubMed 文献 · Radiol Imaging Cancer · 2022-01-01

这项单中心前瞻性单臂研究纳入23例雌激素受体阳性骨-only或骨主导型转移性乳腺癌女性,在新内分泌治疗前、4周和12周行18F-FDG PET/CT,评估早期4周PET/CT预测无进展生存期的价值。4周PET缓解者(靶病灶SUVmax总和下降≥30%)较非缓解者无进展生存期、总生存期和骨相关事件时间数值上更长,但差异均未达统计学显著。

要点

  • 4周时靶病灶SUVmax总和下降≥30%定义为PET缓解,用于早期预测治疗失败。
  • 4周PET缓解者无进展生存期14.2个月 vs 非缓解者6.3个月,P=0.53,未达统计学显著。
  • 4周与12周SUVmax较基线的百分比变化高度相关(r=0.81)。

核心结论

  • 4周18F-FDG PET/CT可能作为早期预测治疗失败的指标,但缓解者与非缓解者间无进展生存期、总生存期和骨相关事件时间差异均未达统计学显著。

研究设计与样本

  • 单中心前瞻性单臂研究,纳入23例活检证实的雌激素受体阳性骨-only或骨主导型转移性乳腺癌女性(中位年龄59岁,范围38-81岁),于2013年10月3日至2018年8月3日间开始新内分泌治疗,在基线、4周和12周行18F-FDG PET/CT,测量最多5个索引病灶的SUVmax和SUVpeak,主要终点为无进展生存期,次要终点为总生存期和骨相关事件时间。

诊断标准与关键数值

  • PET缓解定义为4周或12周时靶病灶SUVmax总和较基线下降30%或以上。
  • 4周与12周SUVmax较基线百分比变化高度相关(r=0.81)。
  • 4周PET缓解者无进展生存期14.2个月 vs 非缓解者6.3个月(P=0.53)。
  • 4周PET缓解者总生存期44.0个月 vs 非缓解者29.7个月(P=0.47)。
  • 4周PET缓解者骨相关事件时间27.4个月 vs 非缓解者25.2个月(P=0.66)。

临床应用与阅片要点

  • 作者提示4周18F-FDG PET/CT可能作为治疗失败的早期预测指标,但各终点差异未达统计学显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT has shown promise for use in assessing treatment response in patients with bone-only or bone-dominant (BD) metastatic breast cancer (mBC). In this single-institution, prospective single-arm study of 23 women (median age, 59 years [range, 38-81 years]) with biopsy-proven estrogen receptor-positive bone-only or BD mBC about to begin new endocrine therapy between October 3, 2013, and August 3, 2018, the value of early 4-week 18F-FDG PET/CT in predicting progression-free survival (PFS) was evaluated. 18F-FDG PET/CT was performed at baseline, 4 weeks, and 12 weeks. Maximum standardized uptake value (SUVmax) and peak SUV (SUVpeak) were measured for up to five index lesions. The primary end point was PFS. Secondary end points were overall survival (OS) and time to skeletal-related events (tSREs). All end points were compared between responders (reduction of 30% or more in the sum of SUVmax for target lesions) and nonresponders at 4 weeks and 12 weeks. Percentage change from baseline in SUVmax at 4- and 12-week 18F-FDG PET/CT were highly correlated (r = 0.81). At the 4-week time point PET responders had numerically longer PFS (14.2 months vs 6.3 months; P = .53), OS (44.0 months vs 29.7 months; P = .47), and tSRE (27.4 months vs 25.2 months; P = .66) compared with nonresponders, suggesting the clinical utility of 4-week 18F-FDG PET/CT as an early predictor of treatment failure. Keywords: Breast Cancer, Metastatic Breast Cancer, Bone-Dominant Metastatic Breast Cancer, FDG PET/CT, Estrogen-Receptor Positive Metastatic Breast Cancer Supplemental material is available for this article. Clinical trial registration no. NCT04316117 © RSNA, 2022.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Makhlin I, Korhonen KE, Martin ML, et al. 18F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer. Radiol Imaging Cancer. 2022. PMID: 36269154. doi:10.1148/rycan.220032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。